| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histone Deacetylases | 74 | 2024 | 210 | 13.080 |
Why?
|
| Histone Deacetylase Inhibitors | 33 | 2023 | 207 | 6.710 |
Why?
|
| Cardiomegaly | 35 | 2025 | 166 | 6.000 |
Why?
|
| Myocytes, Cardiac | 40 | 2025 | 505 | 5.250 |
Why?
|
| Myocardium | 38 | 2025 | 898 | 5.230 |
Why?
|
| Heart Failure | 34 | 2025 | 2048 | 5.000 |
Why?
|
| Fibroblasts | 27 | 2025 | 1000 | 3.160 |
Why?
|
| Fibrosis | 20 | 2024 | 542 | 2.980 |
Why?
|
| Heart | 18 | 2022 | 608 | 2.920 |
Why?
|
| Ventricular Remodeling | 15 | 2025 | 253 | 2.910 |
Why?
|
| Transcription Factors | 33 | 2024 | 1706 | 2.500 |
Why?
|
| Protein Kinase C | 18 | 2015 | 254 | 2.470 |
Why?
|
| Nuclear Proteins | 10 | 2024 | 708 | 2.010 |
Why?
|
| Myofibrils | 8 | 2023 | 48 | 1.960 |
Why?
|
| Signal Transduction | 54 | 2025 | 5060 | 1.930 |
Why?
|
| Epigenesis, Genetic | 13 | 2025 | 646 | 1.920 |
Why?
|
| Animals | 144 | 2025 | 37088 | 1.880 |
Why?
|
| Adipocytes | 5 | 2025 | 227 | 1.730 |
Why?
|
| Myofibroblasts | 5 | 2023 | 127 | 1.720 |
Why?
|
| Thermogenesis | 4 | 2025 | 44 | 1.680 |
Why?
|
| Hypertrophy, Right Ventricular | 4 | 2021 | 145 | 1.660 |
Why?
|
| Rats | 49 | 2022 | 5558 | 1.630 |
Why?
|
| Extracellular Matrix | 6 | 2023 | 534 | 1.450 |
Why?
|
| Chromatin | 10 | 2024 | 517 | 1.440 |
Why?
|
| Cells, Cultured | 37 | 2025 | 4155 | 1.420 |
Why?
|
| Gene Expression Regulation | 32 | 2022 | 2583 | 1.410 |
Why?
|
| Mice | 69 | 2025 | 17748 | 1.360 |
Why?
|
| Rats, Sprague-Dawley | 31 | 2021 | 2467 | 1.300 |
Why?
|
| Dual-Specificity Phosphatases | 3 | 2021 | 11 | 1.260 |
Why?
|
| Protein Processing, Post-Translational | 8 | 2023 | 463 | 1.210 |
Why?
|
| Hypertension, Pulmonary | 11 | 2021 | 1916 | 1.180 |
Why?
|
| Azepines | 4 | 2024 | 97 | 1.150 |
Why?
|
| Heart Ventricles | 13 | 2022 | 731 | 1.150 |
Why?
|
| Histones | 13 | 2020 | 636 | 1.150 |
Why?
|
| Angiotensin II | 5 | 2021 | 97 | 1.090 |
Why?
|
| Triazoles | 4 | 2024 | 155 | 1.090 |
Why?
|
| Adipose Tissue | 4 | 2025 | 643 | 1.030 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2024 | 135 | 1.010 |
Why?
|
| Heart-Assist Devices | 3 | 2025 | 548 | 0.990 |
Why?
|
| Gene Expression Regulation, Enzymologic | 7 | 2019 | 276 | 0.960 |
Why?
|
| Phosphorylation | 27 | 2023 | 1760 | 0.940 |
Why?
|
| Cell Cycle Proteins | 5 | 2024 | 614 | 0.930 |
Why?
|
| DNA-Binding Proteins | 32 | 2005 | 1475 | 0.920 |
Why?
|
| Hydroxamic Acids | 6 | 2018 | 89 | 0.910 |
Why?
|
| Lysine | 6 | 2022 | 288 | 0.910 |
Why?
|
| Vascular Remodeling | 3 | 2021 | 192 | 0.880 |
Why?
|
| Muscle, Skeletal | 12 | 2023 | 1739 | 0.870 |
Why?
|
| Acetylation | 15 | 2020 | 245 | 0.870 |
Why?
|
| Humans | 107 | 2025 | 137601 | 0.840 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2021 | 257 | 0.840 |
Why?
|
| Catecholamines | 1 | 2023 | 89 | 0.820 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2024 | 72 | 0.820 |
Why?
|
| Sarcomeres | 3 | 2022 | 93 | 0.810 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2024 | 365 | 0.800 |
Why?
|
| Heart Diseases | 4 | 2021 | 328 | 0.790 |
Why?
|
| Disease Models, Animal | 23 | 2025 | 4301 | 0.790 |
Why?
|
| Repressor Proteins | 15 | 2019 | 423 | 0.770 |
Why?
|
| Myocardial Infarction | 4 | 2024 | 1052 | 0.770 |
Why?
|
| Adipose Tissue, Brown | 2 | 2023 | 55 | 0.770 |
Why?
|
| Rejuvenation | 1 | 2022 | 19 | 0.760 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 45 | 0.740 |
Why?
|
| Cell Proliferation | 5 | 2021 | 2467 | 0.720 |
Why?
|
| Assisted Circulation | 1 | 2021 | 25 | 0.720 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 358 | 0.710 |
Why?
|
| Mice, Inbred C57BL | 22 | 2025 | 5764 | 0.700 |
Why?
|
| Macrophages | 5 | 2024 | 1544 | 0.700 |
Why?
|
| Heart Murmurs | 1 | 2021 | 14 | 0.700 |
Why?
|
| MEF2 Transcription Factors | 20 | 2020 | 59 | 0.700 |
Why?
|
| Animals, Newborn | 14 | 2017 | 846 | 0.700 |
Why?
|
| Cell Nucleus | 13 | 2015 | 611 | 0.690 |
Why?
|
| Obesity | 4 | 2025 | 2985 | 0.680 |
Why?
|
| Arteries | 1 | 2022 | 261 | 0.670 |
Why?
|
| Epigenomics | 3 | 2021 | 115 | 0.660 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2020 | 56 | 0.660 |
Why?
|
| Aortic Diseases | 1 | 2021 | 117 | 0.660 |
Why?
|
| Muscle Proteins | 6 | 2025 | 237 | 0.640 |
Why?
|
| Histone Deacetylase 6 | 6 | 2022 | 17 | 0.630 |
Why?
|
| NF-kappa B | 11 | 2024 | 678 | 0.630 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 430 | 0.630 |
Why?
|
| Mice, Knockout | 12 | 2024 | 3007 | 0.620 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 12 | 2006 | 174 | 0.610 |
Why?
|
| Pulmonary Artery | 4 | 2021 | 1107 | 0.580 |
Why?
|
| Cardiovascular Agents | 4 | 2025 | 155 | 0.580 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 94 | 0.570 |
Why?
|
| Calcineurin | 12 | 2008 | 107 | 0.570 |
Why?
|
| I-kappa B Proteins | 8 | 2000 | 76 | 0.560 |
Why?
|
| Myogenic Regulatory Factors | 18 | 2009 | 55 | 0.560 |
Why?
|
| Drug Discovery | 2 | 2016 | 145 | 0.550 |
Why?
|
| T-Lymphocytes | 6 | 2022 | 1979 | 0.550 |
Why?
|
| Oxidative Stress | 3 | 2019 | 1319 | 0.540 |
Why?
|
| High-Throughput Screening Assays | 2 | 2016 | 155 | 0.530 |
Why?
|
| Immunotherapy | 1 | 2022 | 628 | 0.530 |
Why?
|
| Models, Biological | 15 | 2022 | 1783 | 0.530 |
Why?
|
| Carrier Proteins | 8 | 2013 | 736 | 0.530 |
Why?
|
| Karyopherins | 2 | 2009 | 19 | 0.530 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2019 | 461 | 0.530 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2021 | 447 | 0.520 |
Why?
|
| Histone Acetyltransferases | 3 | 2014 | 61 | 0.520 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2017 | 174 | 0.510 |
Why?
|
| Male | 54 | 2025 | 67690 | 0.490 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2009 | 206 | 0.490 |
Why?
|
| Blood Pressure | 6 | 2022 | 1720 | 0.480 |
Why?
|
| Fatty Liver | 1 | 2018 | 241 | 0.480 |
Why?
|
| Protein Binding | 13 | 2019 | 2232 | 0.480 |
Why?
|
| Alkaline Phosphatase | 2 | 2017 | 151 | 0.480 |
Why?
|
| Active Transport, Cell Nucleus | 10 | 2010 | 122 | 0.470 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 486 | 0.460 |
Why?
|
| Enzyme Inhibitors | 6 | 2016 | 847 | 0.460 |
Why?
|
| Carbazoles | 1 | 2015 | 49 | 0.450 |
Why?
|
| Transcription, Genetic | 17 | 2014 | 1455 | 0.450 |
Why?
|
| Microtubules | 1 | 2017 | 280 | 0.450 |
Why?
|
| Sumoylation | 1 | 2014 | 15 | 0.450 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.450 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 49 | 0.450 |
Why?
|
| SUMO-1 Protein | 1 | 2014 | 20 | 0.440 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 92 | 0.440 |
Why?
|
| MicroRNAs | 4 | 2021 | 676 | 0.430 |
Why?
|
| Pyrroles | 1 | 2015 | 211 | 0.420 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 87 | 0.410 |
Why?
|
| YY1 Transcription Factor | 2 | 2015 | 22 | 0.410 |
Why?
|
| Induced Pluripotent Stem Cells | 5 | 2025 | 248 | 0.400 |
Why?
|
| Stroke Volume | 6 | 2025 | 569 | 0.400 |
Why?
|
| Transcriptome | 7 | 2025 | 969 | 0.390 |
Why?
|
| Phenotype | 9 | 2025 | 3150 | 0.390 |
Why?
|
| Calcium | 4 | 2023 | 1182 | 0.390 |
Why?
|
| Myocardial Contraction | 5 | 2023 | 301 | 0.380 |
Why?
|
| Hydrogels | 4 | 2025 | 679 | 0.380 |
Why?
|
| Isoenzymes | 7 | 2017 | 303 | 0.370 |
Why?
|
| Enhancer Elements, Genetic | 5 | 2024 | 189 | 0.370 |
Why?
|
| Immunoblotting | 5 | 2014 | 306 | 0.360 |
Why?
|
| Troponin I | 2 | 2023 | 81 | 0.350 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2024 | 102 | 0.350 |
Why?
|
| Cell Culture Techniques | 2 | 2025 | 363 | 0.340 |
Why?
|
| Myosin Heavy Chains | 4 | 2010 | 174 | 0.340 |
Why?
|
| Proteome | 2 | 2025 | 471 | 0.330 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 500 | 0.330 |
Why?
|
| Connectin | 2 | 2022 | 35 | 0.330 |
Why?
|
| Stem Cell Transplantation | 2 | 2021 | 177 | 0.330 |
Why?
|
| Nuclear Localization Signals | 1 | 2010 | 18 | 0.330 |
Why?
|
| RNA Polymerase II | 3 | 2019 | 326 | 0.320 |
Why?
|
| Benzamides | 3 | 2019 | 206 | 0.320 |
Why?
|
| Proteomics | 4 | 2025 | 1109 | 0.320 |
Why?
|
| HEK293 Cells | 4 | 2019 | 730 | 0.320 |
Why?
|
| COS Cells | 9 | 2010 | 183 | 0.320 |
Why?
|
| Cell Line | 17 | 2021 | 2864 | 0.310 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2025 | 323 | 0.310 |
Why?
|
| Ventricular Function, Left | 3 | 2025 | 495 | 0.310 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1152 | 0.300 |
Why?
|
| Protein Isoforms | 4 | 2013 | 391 | 0.290 |
Why?
|
| RNA-Binding Proteins | 3 | 2021 | 427 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 578 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2022 | 149 | 0.280 |
Why?
|
| Aortic Valve | 3 | 2022 | 350 | 0.280 |
Why?
|
| Tissue Engineering | 2 | 2025 | 425 | 0.280 |
Why?
|
| Cell Differentiation | 9 | 2025 | 1999 | 0.280 |
Why?
|
| Inflammation Mediators | 3 | 2021 | 511 | 0.280 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 322 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 2508 | 0.270 |
Why?
|
| Amino Acid Sequence | 12 | 2016 | 2158 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 905 | 0.260 |
Why?
|
| TRPC Cation Channels | 1 | 2006 | 13 | 0.260 |
Why?
|
| Ankyrins | 2 | 2005 | 12 | 0.250 |
Why?
|
| GATA4 Transcription Factor | 4 | 2020 | 18 | 0.240 |
Why?
|
| Female | 28 | 2025 | 73359 | 0.240 |
Why?
|
| Small Molecule Libraries | 2 | 2016 | 94 | 0.240 |
Why?
|
| RNA, Messenger | 9 | 2022 | 2798 | 0.230 |
Why?
|
| Acetyltransferases | 2 | 2002 | 21 | 0.230 |
Why?
|
| Stress, Physiological | 2 | 2006 | 450 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2007 | 308 | 0.230 |
Why?
|
| Citalopram | 1 | 2025 | 32 | 0.230 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 45 | 0.230 |
Why?
|
| Acylation | 2 | 2022 | 31 | 0.230 |
Why?
|
| Aging | 2 | 2015 | 1850 | 0.230 |
Why?
|
| Cortical Bone | 2 | 2021 | 19 | 0.230 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2025 | 40 | 0.230 |
Why?
|
| Deuterium | 1 | 2025 | 99 | 0.220 |
Why?
|
| Proteins | 4 | 2021 | 1011 | 0.220 |
Why?
|
| Nanotubes, Carbon | 1 | 2025 | 48 | 0.220 |
Why?
|
| Calcium Signaling | 4 | 2015 | 249 | 0.220 |
Why?
|
| 3T3-L1 Cells | 2 | 2022 | 37 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 3 | 2021 | 322 | 0.220 |
Why?
|
| Cyclophilins | 1 | 2024 | 39 | 0.220 |
Why?
|
| Estrogens | 2 | 2020 | 368 | 0.220 |
Why?
|
| Hypertension | 3 | 2011 | 1244 | 0.220 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2021 | 873 | 0.210 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2021 | 138 | 0.210 |
Why?
|
| Uncoupling Protein 1 | 1 | 2023 | 16 | 0.210 |
Why?
|
| Sequence Analysis, RNA | 3 | 2021 | 451 | 0.210 |
Why?
|
| Mice, Transgenic | 12 | 2023 | 2165 | 0.210 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2022 | 165 | 0.210 |
Why?
|
| Calcinosis | 2 | 2017 | 235 | 0.210 |
Why?
|
| Adaptation, Physiological | 4 | 2017 | 551 | 0.210 |
Why?
|
| Autophagy | 2 | 2017 | 286 | 0.210 |
Why?
|
| Transcriptional Activation | 7 | 2013 | 373 | 0.210 |
Why?
|
| Hypoxia | 5 | 2013 | 1121 | 0.200 |
Why?
|
| Diet, High-Fat | 3 | 2022 | 248 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 978 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 324 | 0.200 |
Why?
|
| Genetic Therapy | 1 | 2005 | 311 | 0.190 |
Why?
|
| Cell Communication | 1 | 2024 | 315 | 0.190 |
Why?
|
| Valproic Acid | 2 | 2013 | 45 | 0.190 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 803 | 0.190 |
Why?
|
| Endocardium | 1 | 2022 | 30 | 0.190 |
Why?
|
| Enzyme Activation | 6 | 2022 | 818 | 0.190 |
Why?
|
| Metalloproteases | 1 | 2022 | 42 | 0.190 |
Why?
|
| Molecular Sequence Data | 13 | 2011 | 2924 | 0.190 |
Why?
|
| Inflammation | 4 | 2017 | 2841 | 0.190 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2023 | 85 | 0.190 |
Why?
|
| NFATC Transcription Factors | 6 | 2006 | 93 | 0.190 |
Why?
|
| Cell Physiological Phenomena | 1 | 2002 | 19 | 0.190 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2018 | 1074 | 0.180 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
|
| ADAMTS4 Protein | 1 | 2021 | 16 | 0.180 |
Why?
|
| Menopause | 1 | 2025 | 326 | 0.180 |
Why?
|
| Macrophage Activation | 2 | 2021 | 199 | 0.180 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 44 | 0.180 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 1718 | 0.180 |
Why?
|
| Thiazepines | 1 | 2021 | 6 | 0.180 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2001 | 72 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 2023 | 190 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 1047 | 0.180 |
Why?
|
| Homeodomain Proteins | 2 | 2024 | 506 | 0.180 |
Why?
|
| Heart Rate | 1 | 2025 | 785 | 0.170 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2002 | 401 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2021 | 66 | 0.170 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2021 | 72 | 0.170 |
Why?
|
| Structure-Activity Relationship | 6 | 2011 | 568 | 0.170 |
Why?
|
| Biocompatible Materials | 1 | 2025 | 423 | 0.170 |
Why?
|
| Adenylate Kinase | 3 | 2013 | 27 | 0.170 |
Why?
|
| Naphthyridines | 2 | 2010 | 19 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 130 | 0.170 |
Why?
|
| Serine | 5 | 2006 | 141 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 190 | 0.170 |
Why?
|
| Exosomes | 1 | 2021 | 104 | 0.170 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 62 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 413 | 0.170 |
Why?
|
| RNA Interference | 2 | 2013 | 468 | 0.160 |
Why?
|
| Histone Deacetylase 2 | 3 | 2013 | 9 | 0.160 |
Why?
|
| Leptin | 1 | 2022 | 242 | 0.160 |
Why?
|
| Catalytic Domain | 3 | 2015 | 228 | 0.160 |
Why?
|
| Aminopyridines | 2 | 2010 | 97 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2000 | 169 | 0.160 |
Why?
|
| Succinic Acid | 1 | 2019 | 39 | 0.160 |
Why?
|
| Protein Transport | 3 | 2009 | 440 | 0.160 |
Why?
|
| Diastole | 1 | 2020 | 140 | 0.160 |
Why?
|
| Histone Deacetylase 1 | 2 | 2017 | 20 | 0.160 |
Why?
|
| Machine Learning | 1 | 2025 | 516 | 0.160 |
Why?
|
| Serum | 1 | 2019 | 60 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2022 | 276 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2019 | 54 | 0.150 |
Why?
|
| Oxadiazoles | 1 | 2019 | 32 | 0.150 |
Why?
|
| Biomimetics | 1 | 2019 | 43 | 0.150 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2019 | 13 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 274 | 0.150 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2019 | 12 | 0.150 |
Why?
|
| Pyrimidines | 2 | 2013 | 462 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2019 | 21 | 0.150 |
Why?
|
| Energy Metabolism | 3 | 2022 | 920 | 0.150 |
Why?
|
| Receptor Cross-Talk | 1 | 2018 | 21 | 0.150 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 2041 | 0.150 |
Why?
|
| Histone Code | 1 | 2018 | 33 | 0.150 |
Why?
|
| Biopsy | 1 | 2022 | 1089 | 0.150 |
Why?
|
| Wound Healing | 1 | 2021 | 343 | 0.150 |
Why?
|
| Mitochondria, Heart | 1 | 2019 | 100 | 0.140 |
Why?
|
| 3' Untranslated Regions | 2 | 2016 | 145 | 0.140 |
Why?
|
| Adipose Tissue, White | 1 | 2018 | 43 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 176 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 279 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 84 | 0.140 |
Why?
|
| Gold | 1 | 2019 | 118 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 257 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2011 | 619 | 0.140 |
Why?
|
| Middle Aged | 11 | 2025 | 33441 | 0.140 |
Why?
|
| Amides | 2 | 2009 | 94 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 1243 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3550 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2017 | 7 | 0.140 |
Why?
|
| 14-3-3 Proteins | 3 | 2010 | 17 | 0.140 |
Why?
|
| Adenoviridae | 2 | 2011 | 198 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 131 | 0.140 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 79 | 0.130 |
Why?
|
| Myosins | 1 | 2018 | 135 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 257 | 0.130 |
Why?
|
| Protein Domains | 1 | 2019 | 289 | 0.130 |
Why?
|
| Synovial Membrane | 2 | 2016 | 121 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 4 | 2008 | 185 | 0.130 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 13 | 0.130 |
Why?
|
| Calcineurin Inhibitors | 3 | 2004 | 73 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 348 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 160 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2016 | 635 | 0.130 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 1996 | 28 | 0.130 |
Why?
|
| Gap Junctions | 1 | 2017 | 60 | 0.130 |
Why?
|
| Stem Cells | 1 | 2021 | 597 | 0.130 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 1145 | 0.130 |
Why?
|
| Kinetics | 5 | 2025 | 1640 | 0.130 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 210 | 0.130 |
Why?
|
| Tubulin | 2 | 2015 | 145 | 0.130 |
Why?
|
| Kidney | 2 | 2022 | 1469 | 0.130 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2016 | 53 | 0.130 |
Why?
|
| CapZ Actin Capping Protein | 1 | 2016 | 2 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2016 | 1156 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 328 | 0.130 |
Why?
|
| Synoviocytes | 1 | 2016 | 17 | 0.130 |
Why?
|
| Gene Products, tat | 1 | 1996 | 22 | 0.130 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2016 | 23 | 0.130 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 43 | 0.130 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 172 | 0.120 |
Why?
|
| Cell Movement | 4 | 2015 | 971 | 0.120 |
Why?
|
| Pyridines | 2 | 2012 | 498 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 625 | 0.120 |
Why?
|
| Serum Response Factor | 1 | 2016 | 31 | 0.120 |
Why?
|
| Molecular Imaging | 1 | 2016 | 57 | 0.120 |
Why?
|
| Binding Sites | 6 | 2008 | 1316 | 0.120 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2015 | 11 | 0.120 |
Why?
|
| Ischemia | 1 | 2019 | 408 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 295 | 0.120 |
Why?
|
| Hypertrophy | 3 | 2023 | 132 | 0.120 |
Why?
|
| MyoD Protein | 4 | 2002 | 35 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2019 | 598 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 3287 | 0.120 |
Why?
|
| Interleukins | 1 | 2017 | 251 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2017 | 196 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 84 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 273 | 0.110 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2015 | 23 | 0.110 |
Why?
|
| Cellular Reprogramming | 1 | 2015 | 98 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 163 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 5 | 2016 | 1236 | 0.110 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 32 | 0.110 |
Why?
|
| Biocatalysis | 1 | 2014 | 71 | 0.110 |
Why?
|
| Endopeptidases | 1 | 2014 | 90 | 0.110 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2014 | 29 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2016 | 352 | 0.110 |
Why?
|
| Systole | 1 | 2014 | 174 | 0.110 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 231 | 0.110 |
Why?
|
| Transfection | 8 | 2015 | 938 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 40 | 0.100 |
Why?
|
| Physical Exertion | 1 | 2014 | 209 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 212 | 0.100 |
Why?
|
| Interleukin-1beta | 3 | 2024 | 373 | 0.100 |
Why?
|
| Phosphoproteins | 3 | 2001 | 340 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 442 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 183 | 0.090 |
Why?
|
| Recombinant Proteins | 7 | 2017 | 1350 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 150 | 0.090 |
Why?
|
| Endothelin-1 | 2 | 2011 | 177 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 269 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 323 | 0.090 |
Why?
|
| Retroviridae Proteins, Oncogenic | 3 | 1997 | 11 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 433 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2014 | 240 | 0.090 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2011 | 3 | 0.090 |
Why?
|
| Azoles | 1 | 2011 | 4 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 45 | 0.090 |
Why?
|
| Cell Size | 2 | 2016 | 90 | 0.090 |
Why?
|
| Indoles | 1 | 2014 | 409 | 0.090 |
Why?
|
| Cats | 2 | 2022 | 223 | 0.090 |
Why?
|
| Materials Testing | 2 | 2025 | 349 | 0.090 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2010 | 7 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2022 | 2022 | 0.080 |
Why?
|
| Norepinephrine | 1 | 2011 | 191 | 0.080 |
Why?
|
| Rats, Inbred Dahl | 3 | 2020 | 9 | 0.080 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2011 | 129 | 0.080 |
Why?
|
| Consensus Sequence | 1 | 2010 | 72 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 338 | 0.080 |
Why?
|
| Molecular Structure | 2 | 2011 | 495 | 0.080 |
Why?
|
| Estradiol | 1 | 2013 | 524 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 324 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2005 | 552 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 3 | 2004 | 52 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 490 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2018 | 1225 | 0.080 |
Why?
|
| Models, Animal | 1 | 2011 | 392 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2013 | 1193 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 152 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 839 | 0.080 |
Why?
|
| Mutation | 6 | 2014 | 3991 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 106 | 0.080 |
Why?
|
| Embryo, Mammalian | 3 | 2020 | 234 | 0.080 |
Why?
|
| Cytokines | 2 | 2014 | 2075 | 0.080 |
Why?
|
| Cattle | 4 | 2013 | 987 | 0.080 |
Why?
|
| Precipitin Tests | 3 | 2004 | 98 | 0.070 |
Why?
|
| Cell Survival | 3 | 2015 | 1128 | 0.070 |
Why?
|
| Phenylephrine | 2 | 2021 | 74 | 0.070 |
Why?
|
| Aged | 5 | 2025 | 23938 | 0.070 |
Why?
|
| NF-KappaB Inhibitor alpha | 5 | 2000 | 50 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2011 | 239 | 0.070 |
Why?
|
| Aniline Compounds | 1 | 2009 | 102 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2020 | 216 | 0.070 |
Why?
|
| Drug Design | 1 | 2009 | 165 | 0.070 |
Why?
|
| Adult | 8 | 2019 | 37910 | 0.070 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 156 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2025 | 843 | 0.070 |
Why?
|
| Piperazines | 1 | 2010 | 343 | 0.070 |
Why?
|
| Cyclosporine | 2 | 1999 | 268 | 0.070 |
Why?
|
| Swine | 2 | 2021 | 795 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 619 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 3 | 1996 | 623 | 0.070 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2007 | 28 | 0.070 |
Why?
|
| Muscle Fatigue | 1 | 2008 | 98 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2006 | 384 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 181 | 0.060 |
Why?
|
| Diet | 1 | 2014 | 1287 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 111 | 0.060 |
Why?
|
| Rats, Inbred WF | 1 | 2006 | 8 | 0.060 |
Why?
|
| Thiadiazoles | 1 | 2006 | 23 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2006 | 43 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2000 | 328 | 0.060 |
Why?
|
| Biological Transport | 2 | 2013 | 401 | 0.060 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2006 | 21 | 0.060 |
Why?
|
| Apoptosis | 4 | 2021 | 2551 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7609 | 0.060 |
Why?
|
| Anilides | 1 | 2006 | 72 | 0.060 |
Why?
|
| Neurons | 1 | 2015 | 1592 | 0.060 |
Why?
|
| Transcription Factor RelA | 2 | 2024 | 85 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 357 | 0.060 |
Why?
|
| Adenosine Diphosphate | 1 | 2006 | 80 | 0.060 |
Why?
|
| Models, Genetic | 3 | 2004 | 589 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2010 | 407 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 863 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2017 | 390 | 0.060 |
Why?
|
| Nuclear Envelope | 1 | 2006 | 40 | 0.060 |
Why?
|
| Base Sequence | 6 | 2006 | 2180 | 0.060 |
Why?
|
| Cyclohexenes | 1 | 2025 | 6 | 0.060 |
Why?
|
| Vinyl Compounds | 1 | 2025 | 6 | 0.060 |
Why?
|
| Pneumonia | 1 | 2011 | 638 | 0.060 |
Why?
|
| Models, Anatomic | 1 | 2006 | 84 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 551 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 392 | 0.060 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 35 | 0.060 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2024 | 19 | 0.060 |
Why?
|
| Fluoresceins | 1 | 2004 | 49 | 0.060 |
Why?
|
| Adhesins, Bacterial | 1 | 2004 | 40 | 0.060 |
Why?
|
| Injections | 1 | 2025 | 187 | 0.060 |
Why?
|
| Research Design | 2 | 2022 | 1110 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2025 | 148 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2015 | 135 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2011 | 785 | 0.050 |
Why?
|
| Particle Size | 1 | 2025 | 390 | 0.050 |
Why?
|
| Metabolomics | 2 | 2019 | 686 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2025 | 221 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 485 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 348 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6818 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 396 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2023 | 49 | 0.050 |
Why?
|
| Jurkat Cells | 2 | 2000 | 138 | 0.050 |
Why?
|
| Methylation | 2 | 2019 | 228 | 0.050 |
Why?
|
| Action Potentials | 2 | 2017 | 484 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 226 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 318 | 0.050 |
Why?
|
| Cell Division | 2 | 2002 | 790 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2002 | 25 | 0.050 |
Why?
|
| Carbamates | 1 | 2023 | 50 | 0.050 |
Why?
|
| Sex Factors | 2 | 2022 | 2046 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 424 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 851 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2019 | 765 | 0.050 |
Why?
|
| Temperature | 1 | 2025 | 664 | 0.050 |
Why?
|
| Massachusetts | 1 | 2022 | 173 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2022 | 66 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2001 | 2 | 0.050 |
Why?
|
| Gene Expression | 4 | 2016 | 1485 | 0.050 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2001 | 14 | 0.050 |
Why?
|
| RNA, Small Nucleolar | 1 | 2021 | 8 | 0.050 |
Why?
|
| Rats, Transgenic | 1 | 2021 | 19 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 126 | 0.050 |
Why?
|
| Rats, Inbred BN | 1 | 2021 | 56 | 0.050 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2001 | 27 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2021 | 88 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 95 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2001 | 182 | 0.040 |
Why?
|
| American Heart Association | 1 | 2022 | 284 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2025 | 818 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2015 | 1221 | 0.040 |
Why?
|
| Muscle Development | 1 | 2001 | 115 | 0.040 |
Why?
|
| Cytoplasm | 3 | 2015 | 267 | 0.040 |
Why?
|
| Culture Media | 1 | 2021 | 163 | 0.040 |
Why?
|
| DNA Primers | 3 | 1996 | 508 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 718 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 850 | 0.040 |
Why?
|
| Muscle Cells | 2 | 2010 | 42 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1921 | 0.040 |
Why?
|
| Cell Death | 1 | 2002 | 373 | 0.040 |
Why?
|
| Peptides | 1 | 2006 | 980 | 0.040 |
Why?
|
| Genes, ras | 1 | 2000 | 94 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2000 | 182 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2000 | 93 | 0.040 |
Why?
|
| Serotonin | 2 | 2016 | 321 | 0.040 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 8 | 0.040 |
Why?
|
| Lung | 3 | 2020 | 4057 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2007 | 1118 | 0.040 |
Why?
|
| Pregnancy | 2 | 2022 | 6770 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 60 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 240 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1999 | 118 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 219 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2008 | 392 | 0.040 |
Why?
|
| RNA | 1 | 2004 | 926 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 745 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 445 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1425 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 226 | 0.030 |
Why?
|
| Body Weight | 1 | 2022 | 980 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2000 | 530 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2017 | 12 | 0.030 |
Why?
|
| Autoradiography | 1 | 2017 | 68 | 0.030 |
Why?
|
| Papio | 1 | 2017 | 94 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2017 | 73 | 0.030 |
Why?
|
| Enzyme Repression | 1 | 2016 | 6 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 3 | 2000 | 5 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2019 | 416 | 0.030 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2016 | 24 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 497 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2016 | 71 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 174 | 0.030 |
Why?
|
| Multienzyme Complexes | 1 | 1996 | 69 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 73 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 633 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2016 | 92 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2004 | 662 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 628 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 637 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 351 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2015 | 17 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1996 | 157 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2010 | 1597 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cardiomegaly, Exercise-Induced | 1 | 2014 | 3 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2014 | 21 | 0.030 |
Why?
|
| Clathrin | 1 | 1995 | 28 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1997 | 391 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Muscle Fibers, Slow-Twitch | 2 | 2008 | 15 | 0.030 |
Why?
|
| Soybean Proteins | 1 | 2014 | 14 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 98 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 33 | 0.030 |
Why?
|
| Caseins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Trypanosoma cruzi | 1 | 2015 | 40 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1997 | 361 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 310 | 0.030 |
Why?
|
| Ketocholesterols | 1 | 2014 | 7 | 0.030 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 24 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 156 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 133 | 0.030 |
Why?
|
| Azetidines | 1 | 2014 | 43 | 0.030 |
Why?
|
| Simvastatin | 1 | 2014 | 60 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 197 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2014 | 82 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2014 | 435 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 172 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 418 | 0.030 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1752 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2013 | 43 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 74 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 243 | 0.030 |
Why?
|
| Blood-Retinal Barrier | 1 | 2013 | 13 | 0.030 |
Why?
|
| Protein Kinase C-delta | 1 | 2013 | 48 | 0.030 |
Why?
|
| Calmodulin | 2 | 2006 | 73 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 64 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 116 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1872 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 950 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 41 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 121 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 200 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 198 | 0.020 |
Why?
|
| Retroviridae | 1 | 1993 | 102 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 201 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 411 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 448 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 92 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 2004 | 360 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1260 | 0.020 |
Why?
|
| Oncogene Proteins v-rel | 3 | 1997 | 3 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2004 | 272 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2011 | 38 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-rel | 3 | 1996 | 7 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 1995 | 611 | 0.020 |
Why?
|
| Chick Embryo | 3 | 1997 | 127 | 0.020 |
Why?
|
| Aorta, Thoracic | 2 | 2007 | 269 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2002 | 145 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 408 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 1995 | 596 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1993 | 368 | 0.020 |
Why?
|
| Retina | 1 | 2013 | 302 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 134 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 384 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 10813 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2014 | 399 | 0.020 |
Why?
|
| MADS Domain Proteins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 465 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 673 | 0.020 |
Why?
|
| Colorado | 1 | 2019 | 4515 | 0.020 |
Why?
|
| Neoplasms | 1 | 2004 | 2691 | 0.020 |
Why?
|
| Monocytes | 1 | 2011 | 563 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 2365 | 0.020 |
Why?
|
| Phospholipase C gamma | 1 | 2008 | 29 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2008 | 33 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2008 | 129 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 86 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2007 | 59 | 0.020 |
Why?
|
| Brain | 1 | 1999 | 2725 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 165 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2840 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2006 | 28 | 0.020 |
Why?
|
| Nucleus Accumbens | 1 | 2007 | 148 | 0.020 |
Why?
|
| Cocaine | 1 | 2007 | 167 | 0.010 |
Why?
|
| Chickens | 1 | 2006 | 189 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 275 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2006 | 132 | 0.010 |
Why?
|
| Reward | 1 | 2007 | 248 | 0.010 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2004 | 12 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2006 | 155 | 0.010 |
Why?
|
| United States | 1 | 2022 | 14925 | 0.010 |
Why?
|
| DNA | 2 | 2003 | 1448 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2004 | 46 | 0.010 |
Why?
|
| Rabbits | 1 | 2006 | 765 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 314 | 0.010 |
Why?
|
| Tritium | 1 | 2003 | 71 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 47 | 0.010 |
Why?
|
| Ventricular Myosins | 1 | 2003 | 29 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 9539 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 2002 | 24 | 0.010 |
Why?
|
| Leucine | 1 | 2003 | 115 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2008 | 785 | 0.010 |
Why?
|
| Emotions | 1 | 2007 | 561 | 0.010 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2002 | 3 | 0.010 |
Why?
|
| Methyltransferases | 1 | 2002 | 71 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 757 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2002 | 101 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2002 | 82 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 1788 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 514 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 59 | 0.010 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2002 | 134 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2000 | 60 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2001 | 62 | 0.010 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2000 | 17 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 224 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 227 | 0.010 |
Why?
|
| Luciferases | 1 | 2000 | 149 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 353 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 13203 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 1999 | 42 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 307 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2000 | 274 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1999 | 49 | 0.010 |
Why?
|
| Ligation | 1 | 1999 | 92 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1999 | 46 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 318 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 320 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 156 | 0.010 |
Why?
|
| Fetus | 1 | 2003 | 801 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 534 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2000 | 688 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2000 | 229 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 21435 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 1997 | 49 | 0.010 |
Why?
|
| Child | 1 | 2017 | 21833 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 347 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 28 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 75 | 0.010 |
Why?
|
| Aorta | 1 | 1999 | 414 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1996 | 143 | 0.010 |
Why?
|
| src Homology Domains | 1 | 1996 | 39 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 826 | 0.010 |
Why?
|
| Gene Products, tax | 1 | 1995 | 13 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 164 | 0.010 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1995 | 45 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 945 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 620 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1995 | 373 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1999 | 1382 | 0.010 |
Why?
|
| Transcription Factor RelB | 1 | 1993 | 3 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1993 | 25 | 0.010 |
Why?
|
| Antibodies | 1 | 1995 | 406 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1996 | 691 | 0.010 |
Why?
|
| Birds | 1 | 1993 | 97 | 0.010 |
Why?
|
| Spleen | 1 | 1993 | 521 | 0.010 |
Why?
|
| HIV-1 | 1 | 1995 | 887 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1993 | 1385 | 0.000 |
Why?
|